Investigating new standards for prophylaxis in reduction of exacerbations - The INSPIRE study methodology

COPD: Journal of Chronic Obstructive Pulmonary Disease

Volumn 4, Issue 3, 2007, Pages 177-183

  Seemungal, Terence ^a   Stockley, Robert ^b   Calverley, Peter ^c   Hagan, Gerry ^d   Wedzicha, Jadwiga A ^e,f  

^a UNIVERSITY OF THE WEST INDIES   (Trinidad and Tobago)

^b QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^c UNIVERSITY HOSPITAL AINTREE   (United Kingdom)

^d GLAXOSMITHKLINE   (United Kingdom)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

^f ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

Bronchodilators; Chronic obstructive pulmonary disease; Fluticasone propionate; Inhaled corticosteroids; Salmeterol; Tiotropium bromide

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL; METHYLPREDNISOLONE; PLACEBO; PREDNISOLONE; SALMETEROL; TIOTROPIUM BROMIDE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE EXACERBATION; DOUBLE BLIND PROCEDURE; HUMAN; MAJOR CLINICAL STUDY; MEDICAL ASSESSMENT; MULTICENTER STUDY; PRIORITY JOURNAL; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; ST GEORGE RESPIRATORY QUESTIONNAIRE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT REFUSAL; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ALBUTEROL; ANDROSTADIENES; BRONCHODILATOR AGENTS; CHOLINERGIC ANTAGONISTS; HUMANS; MIDDLE AGED; MULTICENTER STUDIES AS TOPIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN; SCOPOLAMINE DERIVATIVES;

EID: 34548306914     PISSN: 15412555     EISSN: 15412563     Source Type: Journal    
DOI: 10.1080/15412550701407862     Document Type: Article

References (44)

1. Agusti AG, Noguera A, Sauleda J, Sala E, Pons J, Busquets X. Systemic effects of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(2):347-360.
2. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease - updated 2005. Modena: Global Initiative for Chronic Obstructive Lung Disease, 2005.
3. Agusti AG. COPD, a multicomponent disease: implications for management. Respir Med 2005; 99(6):670-682.
4. Gompertz S, Bayley DL, Hill SL, Stockley RA. Relationship between airway inflammation and the frequency of exacerbations in patients with smoking related COPD. Thorax 2001; 56(1):36-41.
5. Seemungal T, Harper-Owen R, Bhowmik A, Moric I, Sanderson G, Message S, Maccallum P, Meade TW, Jeffries DJ, Johnston SL, Wedzicha JA. Respiratory viruses, symptoms, and inflammatory markers in acute exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(9):1618-1623.
6. Hurst JR, Perera WR, Wilkinson TM, Donaldson GC, Wedzicha JA. Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006; 173(1):71-78.
7. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. Br Med J 2000; 320(7245):1297-1303.
8. Pauwels RA, Lofdahl CG, Laitinen LA, Schouten JP, Postma DS, Pride NB, Ohlsson SV. Long-term treatment with inhaled budesonide in persons with mild chronic obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive Pulmonary Disease. N Engl J Med 1999; 340(25):1948-1953.
9. Calverley P, Pauwels R, Vestbo J, Jones P, Pride N, Gulsvik A, Anderson J, Maden C. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356):449-456.
10. Szafranski W, Cukier A, Ramirez A, Menga G, Sansores R, Nahabedian S, Peterson S, Olsson H. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J 2003; 21(1):74-81.
11. Vestbo J. The TORCH (TOwards a Revolution in COPD Health) survival study protocol. Eur Respir J 2004; 24(2):206-210.
12. Aaron SD, Vandemheen K, Fergusson D, Fitzgerald M, Maltais F, Bourbeau J, Goldstein R, McIvor A, Balter M, O'Donnell D. The Canadian Optimal Therapy of COPD Trial: design, organization and patient recruitment. Can Respir J 2004; 11(8):581-585.
13. Decramer M, Celli B, Tashkin DP, Pauwels RA, Burkhart D, Cassino C, Kesten S. Clinical trial design considerations in assessing long-termfunctional impacts of tiotropium in COPD: The Uplift trial. J Chron Obstruct Pulmon Dis 2004; 1(2):303-312.
14. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2):196-204.
15. Vincken W, van Noord JA, Greefhorst AP, Bantje TA, Kesten S, Korducki L, Cornelissen PJ. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur Respir J 2002; 19(2):209-216.
16. Niewoehner DE, Rice K, Cote C, Paulson D, Cooper JA, Jr., Korducki L, Cassino C, Kesten S. Prevention of exacerbations of chronic obstructive pulmonary disease with tiotropium, a oncedaily inhaled anticholinergic bronchodilator: a randomised trial. Ann Intern Med 2005; 143(5):317-326.
17. Mahler DA, Donohue JF, Barbee RA, Goldman MD, Gross NJ, Wisniewski ME, Yancey SW, Zakes BA, Rickard KA, Anderson WH. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115(4):957-965.
18. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6):912-919.
19. Kardos P, Wencker M, Glaab T, Vogelmeier C. Combination therapy with salmeterol and fluticasone propionate (SFC) is more effective than salmeterol (SAL) alone in reducing exacerbations of COPD. Eur Respir J 2005; 26(Suppl 49):292S.
20. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease. Executive Summary. NHLBI/WHO Workshop Report, 2006.
21. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med 1991; 85 (Suppl B):25-31.
22. Andersson F, Borg S, Jansson SA, Jonsson AC, Ericsson A, Prutz C, Ronmark E, Lundback B. The costs of exacerbations in chronic obstructive pulmonary disease (COPD). Respir Med 2002; 96(9):700-708.
23. Soler-Cataluna JJ, Martinez-Garcia MA, Roman SP, Salcedo E, Navarro M, Ochando R. Severe acute exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11):925-931.
24. Price MJ, Hurrell C, Efthimiou J, Medley HV. Health care costs of treating exacerbations of chronic obstructive pulmonary disease (COPD). Eur Respir J 2005; 14(Suppl):30S.
25. European Respiratory Society & European Lung Foundation. European lung white book. The first comprehensive survey on respiratory health in Europe, 2003.
26. Spencer S, Calverley PM, Sherwood BP, Jones PW. Health status deterioration in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163(1):122-128.
27. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117(5 Suppl 2):398S-401S.
28. Pauwels R, Calverley P, Buist AS, Rennard S, Fukuchi Y, Stahl E, Lofdahl CG. COPD exacerbations: the importance of a standard definition. Respir Med 2004; 98(2):99-107.
29. Wedzicha JA, Seemungal TA, MacCallum PK, Paul EA, Donaldson GC, Bhowmik A, Jeffries DJ, Meade TW. Acute exacerbations of chronic obstructive pulmonary disease are accompanied by elevations of plasma fibrinogen and serum IL-6 levels. Thromb Haemost 2000; 84(2):210-215.
30. Spencer S, Jones PW. Time course of recovery of health status following an infective exacerbation of chronic bronchitis. Thorax 2003; 58(7):589-593.
31. Sin DD, Wu L, Anderson JA, Anthonisen NR, Buist AS, Burge PS, Calverley PM, Connett JE, Lindmark B, Pauwels RA, Postma DS, Soriano JB, Szafranski W, Vestbo J. Inhaled corticosteroids and mortality in chronic obstructive pulmonary disease. Thorax 2005; 60(12):992-997.
32. Wouters EF. Economic analysis of the Confronting COPD survey: an overview of results. Respir Med 2003; 97(Suppl C):S3-14.
33. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1):1418-1422.
34. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2000; 161(5):1608-1613.
35. Calverley P, Pauwels DR, Lofdahl CG, Svensson K, Higenbottam T, Carlsson LG, Stahl E. Relationship between respiratory symptoms and medical treatment in exacerbations of COPD. Eur Respir J 2005; 26(3):406-413.
36. Sin DD, Lacy P, York E, Man SF. Effects of fluticasone on systemic markers of inflammation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 170(7):760-765.
37. de Torres JP, Cordoba-Lanus E, Lopez-Aguilar C, de Fuentes MM, de Garcini AM, Aguirre-Jaime A, Celli BR, Casanova C. Creactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J 2006; Feb 2: [Epub ahead of print].
38. Donaldson GC, Seemungal TA, Patel IS, Bhowmik A, Wilkinson TM, Hurst JR, MacCallum PK, Wedzicha JA. Airway and systemic inflammation and decline in lung function in patients with COPD. Chest 2005; 128(4):1995-2004.
39. Kanner RE, Anthonisen NR, Connett JE. Lower respiratory illnesses promote FEV(1) decline in current smokers but not exsmokers with mild chronic obstructive pulmonary disease: results from the lung health study. Am J Respir Crit Care Med 2001; 164(3):358-364.
40. Broekhuizen R, Wouters EF, Creutzberg EC, Schols AM. Raised CRP levels mark metabolic and functional impairment in advanced COPD. Thorax 2006; 61(1):17-22.
41. Jones PW, Stahl E. Does short-term treatment intensification influence long-term treatment effects on health status in COPD? Eur Respir J 2005; 26(Suppl 49):293S.
42. Jarad NA, Wedzicha JA, Burge PS, Calverley PM. An observational study of inhaled corticosteroid withdrawal in stable chronic obstructive pulmonary disease. ISOLDE Study Group. Respir Med 1999; 93(3):161-166.
43. Stockley RA, Chopra N, Rice L. Addition of salmeterol to existing treatment in patients with COPD: a 12 month study. Thorax 2006; 61(2):122-128.
44. Casaburi R, Mahler DA, Jones PW, Wanner A, San PG, ZuWallack RL, Menjoge SS, Serby CW, Witek T, Jr. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19(2):217-224.